Swiss National Bank Boosts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Swiss National Bank lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.4% in the third quarter, HoldingsChannel reports. The firm owned 540,780 shares of the medical research company’s stock after purchasing an additional 1,900 shares during the quarter. Swiss National Bank’s holdings in IQVIA were worth $128,149,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Thrivent Financial for Lutherans lifted its position in IQVIA by 20.6% in the third quarter. Thrivent Financial for Lutherans now owns 43,177 shares of the medical research company’s stock worth $10,231,000 after buying an additional 7,369 shares during the last quarter. Maxwell Wealth Strategies Inc. lifted its position in IQVIA by 37.3% in the third quarter. Maxwell Wealth Strategies Inc. now owns 11,570 shares of the medical research company’s stock worth $2,742,000 after buying an additional 3,145 shares during the last quarter. Natixis Advisors LLC lifted its position in IQVIA by 26.9% in the third quarter. Natixis Advisors LLC now owns 245,136 shares of the medical research company’s stock worth $58,090,000 after buying an additional 51,970 shares during the last quarter. Mizuho Securities USA LLC lifted its position in IQVIA by 1,397.9% in the third quarter. Mizuho Securities USA LLC now owns 210,428 shares of the medical research company’s stock worth $49,865,000 after buying an additional 196,380 shares during the last quarter. Finally, Simplify Asset Management Inc. lifted its position in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IQV has been the subject of several research analyst reports. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. JPMorgan Chase & Co. decreased their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. The Goldman Sachs Group decreased their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. UBS Group lifted their target price on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $259.13.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $191.19 on Tuesday. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market capitalization of $34.70 billion, a PE ratio of 25.09, a P/E/G ratio of 1.98 and a beta of 1.51. The company has a 50-day simple moving average of $225.96 and a two-hundred day simple moving average of $228.02.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.